Heterocyclic compounds

US7122665B2 · kind B2 · utility

Assignee

• Synta Pharmaceuticals Corp. · US

Inventors

• Lijun Sun · Harvard, US
• Mitsunori Ono · Lexington, US
• Yumiko Wada · Waltham, US
• Weiwen Ying · Ayer, US
• Teresa Przewloka · Tewksbury, US
• Elena Kostik · Arlington, US

Key dates

• Filing date: Oct 14, 2003
• Grant date: Oct 17, 2006
• Expiry date: Mar 19, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D473/18
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention features a compound of formula (I):R1 is aryl or heteroaryl; each of R2 and R4, independently, is H, halogen, CN, alkyl, ORa, or NRaRb; R3 is H, halogen, CN, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, ORa, OC(O)Ra, OC(O)NRaRb, NRaRb, NRaC(O)Rb, NRaS(O)Rb, NRaS(O)2Rb, NRaC(O)NRbRc, NRaC(S)NRbRc, NRaC(NRb)NRcRd, NRaC(O)ORb, S(O)NRaRb, S(O)2NRaRb, S(O)Ra, S(O)2Ra, C(O)Ra, C(O)ORa, or C(O)NRaRb; R5 is H or alkyl; n is 0, 1, 2, 3, 4, 5, or 6; A is O, S, S(O), S(O)2, or NRe; B is N or CRf; X is O, S, S(O), S(O)2, NRe, or C(O); Y is a covalent bond, C(O), C═NRa, O, S, S(O), S(O)2, or NRe; Z is N or CH; each of U and V, independently, is N or CR; and W is O, S, or NRe; in which each of Ra, Rb, Rc, and Rd, independently, is H, alkyl, aryl, heteroaryl, cyclyl, or heterocyclyl; Re is H, alkyl, aryl, acyl, or sufonyl; and Rf is H, alkyl, aryl, acyl, sulfonyl, alkoxyl, amino, ester, amide, CN, or halogen. The compound is useful for treating an interleukin-12 overproduction-related disorder.